《Table 2 Studies of cell-based therapies with immunomodulatory properties in animal models of Alzhei

《Table 2 Studies of cell-based therapies with immunomodulatory properties in animal models of Alzhei   提示：宽带有限、当前游客访问压缩模式
本系列图表出处文件名：随高清版一同展现
《Amelioration of Alzheimer's disease pathology and cognitive deficits by immunomodulatory agents in animal models of Alzheimer's disease》


  1. 获取 高清版本忘记账户？点击这里登录
  1. 下载图表忘记账户？点击这里登录

The five animal studies utilizing these cell-based therapies are summarized in Table 2.Four of these studies had used mouse models，and one a rat model.In the mouse studies，the ages of the animals at which treatment was started ranged from 4 to 16 months and where gender was specified 1 had used males，and 1 both males and females.The rat study had used males 9 to 10 weeks of age.The treatment period with the cell-based therapy ranged from 7 days to 8 months.

图表编号XD0040618100    严禁用于非法目的
绘制时间2019.07.01
作者Bridget Martinez、Philip V.Peplow
绘制单位Department of Molecular & Cellular Biology,University of California、Department of Medicine,St.Georges University School of Medicine、Department of Physics and Engineering,Los Alamos National Laboratory、Department of Anatomy,University of Otago
更多格式高清、无水印（增值服务）

相关图表

  1. 《Table 4 Combination therapy of stem cells with neurotrophic factors in amyotrophic lateral sclerosis》2020.05.26
  2. 《Table 4 Combination therapy of stem cells with neurotrophic factors in amyotrophic lateral sclerosis》2020.05.26
  3. 《Table 3 Combination therapy of stem cells with neurotrophic factors in Huntington's disease》2020.05.26
  4. 《Table 2 Combination therapy of stem cells with neurotrophic factors in Parkinson’s disease》2020.05.26
  5. 《Table 1 Demographics of patients with inflammatory bowel disease included in the studies》2019.07.28
  6. 《Table 1 Non-selective beta-blockers“window therapy”hypothesis-studies analyses》2019.07.14
  7. 《Table 1 Non-selective beta-blockers“window therapy”hypothesis-studies analyses》2019.07.14
  8. 《表4 有关胃NEC和MANEC辅助治疗的研究Figure4 Studies on adjuvant therapy of gastric NEC and MANEC》2019.05.25
  9. 《Table 1 Characteristics of included studies:Evaluating vitamin D treatment in children with inflammatory bowel disease》2019.01.22
  10. 《Table 2–Comparison of the major VOCs (ppbv, unless otherwise stated) with previous studies.》2019.05.15
  11. 《Table 2–Comparison of the major VOCs (ppbv, unless otherwise stated) with previous studies.》2019.05.15
  12. 《Table 1 Studies of pharmacological therapies with immunomodulatory properties in animal models of Alzheimer’s disease (A》2019.07.01
  13. 《Table 1 Studies of pharmacological therapies with immunomodulatory properties in animal models of Alzheimer’s disease (A》2019.07.01
  14. 《Table 1 Studies of pharmacological therapies with immunomodulatory properties in animal models of Alzheimer’s disease (A》2019.07.01
  15. 《Table 2 Studies of cell-based therapies with immunomodulatory properties in animal models of Alzheimer’s disease (AD)》2019.07.01
  16. 《Table 2 The raw data with BCVA and VF of the included studies》2019.01.18
  17. 《Table 6.The flux comparison with previous studies for Fcont.》2018.06.30
  18. 《表1 正在进行的脑转移性NSCLC放射治疗和免疫治疗研究综述Tab 1 Summary of ongoing studies combining radiation therapy and immunotherapy in NSCLC wi》2018.08.20
  19. 《Table 2 Current therapies for patients with CF92and PCD95》2018.04.01
  20. 《Table 2 Studies that identified LPRD with objective diagnostic tools》2019.10.06

随机翻阅

《表5 堵漏材料对钻井液滤失性能及封堵性能的影响》 《表3 1986—2002年南召县各层高度年平均气温表》 《表1 工作时间的离散化：电能表故障预测的代价敏感模型研究》 《表4 全球活跃人工智能企业分布》 《表7 验证数据预测结果：基于多尺度特征提取的电力客户欠费风险预测》 《表1 比较两组临床疗效 (n、%)》 《表1 文教版社会科 (2015年版) 教材中的地图学习内容分布2》 《表3 TETRA与TD-LTE语音业务能力对比Tab.3 Comparison of voice service of TETRA and TD-LTE》 《Table 2 Geological Elements of the 1:5000000 International Geological Map of Asia》 《表1 样品的燃烧性能及氧指数》